Duvelisib (IPI-145)

目录号:S7028 别名: INK1197 中文名称:杜韦利西布

仅限科研使用

Duvelisib (IPI-145, INK1197) 是一种新型选择性PI3K δ/γ抑制剂,在无细胞试验中KiIC50分别为 23 pM/243 pM 和 1 nM/50 nM,对 PI3K δ/γ 的选择性比对其它蛋白激酶高。Phase 3。

Duvelisib (IPI-145) Chemical Structure

CAS: 1201438-56-3

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1557.22 现货
RMB 1409.65 现货
RMB 7967.14 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Duvelisib (IPI-145)发表文献37篇:

产品安全说明书

PI3K抑制剂选择性比较

相关PI3K产品

生物活性

产品描述 Duvelisib (IPI-145, INK1197) 是一种新型选择性PI3K δ/γ抑制剂,在无细胞试验中KiIC50分别为 23 pM/243 pM 和 1 nM/50 nM,对 PI3K δ/γ 的选择性比对其它蛋白激酶高。Phase 3。
靶点
PI3Kδ [1]
(Cell-free assay)
PI3Kβ [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
23 pM(Ki) 1564 pM(Ki) 243 pM(Ki)
体外研究

IPI-145抑制鼠/人类 B细胞增殖,EC50 为0.5 nM/0.5 nM,也抑制人类T细胞增殖,EC50为9.5 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jurkat M4eyS3Bzd2yrZnXyZZRqd25iYYPzZZk> MoToN{Bl[Xm| MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEq3cnvheEBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OD1zLkmg{rxu NHnieG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+
MOLT4 MYnQdo9tcW[ncnH0bY9vKGG|c3H5 NIT6cWM{KGSjeYO= M4f4d2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGlEPTB;Mj6zJO69VQ>? NEWyclg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+
MV4-11 NFm3bnZRem:uaX\ldoF1cW:wIHHzd4F6 NFXCXlA{KGSjeYO= MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OD12LkSg{txO MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
MOLM14 NHLqUZpRem:uaX\ldoF1cW:wIHHzd4F6 MVOzJIRigXN? NWey[FlISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTRiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUC9NU4zKM7:TR?= M4HtT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
Loucy NV7rZ2Y3WHKxbHnm[ZJifGmxbjDhd5NigQ>? MXmzJIRigXN? NUfnO3lsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMc5VkgSClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3ME2wMlk5KM7:TR?= NEXpepM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+
JURKAT NEjxO|BHfW6ldHnvckBie3OjeR?= M3i1XFAvOSxiMT6wMEBidmRiOT6wJO69VQ>? NX7pb4NFUVCLMUS1JJdieyCjYnzlJJRwKGmwaHnibZQhSWu2IHHu[EBUPiCyaH;zdIhwenmuYYTpc44h[W6mIH3v[IV{fGy7IHHm[oVkfGWmIHfyc5d1cCCrbjDKWXJMSVR? NFXXWII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEm3NFI3Oyd-M{C5O|AzPjN:L3G+
MOLT3 NHfhNHVHfW6ldHnvckBie3OjeR?= Ml3LNE4yNCBzLkCsJIFv\CB7LkCg{txO M3voUmlRUTF2NTD3ZZMh[WKuZTD0c{BqdmirYnn0JGFsfCCjbnSgV|YheGixc4Doc5J6dGG2aX;uJIJ2fCCkYYLlcJkh[W[oZXP0[YQhfGinIHfyc5d1cCCxZjDNU2xVOyCWLVHMUC=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl5MEK2N{c,OzB7N{CyOlM9N2F-
Raji32 NELLTItHfW6ldHnvckBie3OjeR?= MnqzNUDPxE1? MkXU[YZn\WO2aY\lcJkhcW2yYXny[YQhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBb5Q> NXriZ2g6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C1PFQzPTRpPkOwOVg1OjV2PD;hQi=>
Ramos460 NITtb41HfW6ldHnvckBie3OjeR?= NX3rVolzOSEQvF2= MWnl[oZm[3SrdnXsfUBqdXCjaYLl[EB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> M3;3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUi0NlU1Lz5|MEW4OFI2PDxxYU6=
HBL-1 MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkXrS2k2OD13LkOg{txO MkPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
OCI-Ly3 MnPFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYfZ[XNFT0l3ME2zMlch|ryP NF\YZ|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
TMD-8 NHzBVmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIDobJJIUTVyPUCuNFAxPSEQvF2= NI\Sdm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
U-2932 MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUnHTVUxRTFwODFOwG0> Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
Farage MkfBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHLSRYRIUTVyPUCuNFQh|ryP M{TkflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
SU-DHL-10 M3LjUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHX1R|BIUTVyPUKuOEDPxE1? M4\jO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
SU-DHL-4 M4rEPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF7XPIRIUTVyPUCuNkDPxE1? Ml63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
Karpas-422 NXvJbGJsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NI\2NVJIUTVyPUCuNUDPxE1? M1XBVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
DOHH-2 M1u3XWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{\XWmdKPTB;MD6wOUDPxE1? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB4N{e3NUc,OzByNke3O|E9N2F-
WSU-NHL NH;sW2JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlPqS2k2OD1yLkCwPEDPxE1? NUXkdVZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
Jeko-1 MmO5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXuyOlZnT0l3ME2xMlMh|ryP M3jRR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
Mino MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWjCW45UT0l3ME2zMlQh|ryP NHjvUnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
NCI-H929 MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfHTVUxRTFizszN MnvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
HH MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUKyeXZiT0l3ME2wMlAyKM7:TR?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB4N{e3NUc,OzByNke3O|E9N2F-
BJAB NGDnfWVE\WyuII\pZYJqdGm2eTDhd5NigQ>? NXXRNWc3OC5zLDCxMEA2KM7:TR?= MmrROFgh[W6mIEeyJIg> Ml70bY5pcWKrdHXkJINmdGxiZ4Lve5Rp NFjSfoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyNlI4QCd-Mkm1NlIzPzh:L3G+
LCL MUPD[YxtKH[rYXLpcIl1gSCjc4PhfS=> NU\Fbnc2OC5zLDCxMEA2KM7:TR?= NWexVol5PDhiYX7kJFczKGh? NEGyb5RqdmirYnn0[YQh[2WubDDndo94fGh? M4\iO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUKyNlc5Lz5{OUWyNlI4QDxxYU6=
insect cells NYC3NVR2TnWwY4Tpc44h[XO|YYm= MmLQOUBucW6| NVr0[|VlUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDDMZRmem2rbnHsJGhqezZvdHHn[4VlKHBzMUDnZY1u[SCneIDy[ZN{\WRiaX6gbY5{\WO2IHPlcIx{KHW|aX7nJJBpd3OyaHH0bYR6dGmwb4PpeI9tKGG|IIP1ZpN1emG2ZTDpckBxemW|ZX7j[UBw\iCpYX3tZU0{OlBvQWTQJIFnfGW{IEWgcYlveyCkeTD0bIlvKGyjeXXyJINpem:vYYTv[5JieGirYzDt[ZRpd2RuIFnDOVAhRSByLkGg{txONg>? M2mxfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMxOzl3MEKvK|5EcEWPQly8M4E,
Sf21 MXTGeY5kfGmxbjDhd5NigQ>? MV[1JI1qdnN? NFXiTWJKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhemWlb33ibY5idnRiZoXscE1t\W6pdHigbJVu[W5icEGxNIRmdHSjL4XueIFo\2WmIILlZ49u[mmwYX70JIZ2dGxibHXu[5RpKHB6NXHsdIhiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jJzIHPlcIx{KHW|aX7nJJBpd3OyaHH0bYR6dGmwb4PpeI9tKGG|IIP1ZpN1emG2ZTDpckBxemW|ZX7j[UBw\iCpYX3tZU0{OlBvQWTQJIFnfGW{IEWgcYlveyCkeTD0bIlvKGxuIFnDOVAhRSByLkGg{txONg>? MlPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|A{QTVyMj:nQmNpTU2ETEyvZV4>
splenic B NV;nZ3FQSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MmP3N|AhdWmwcx?= NWfk[HhuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBD[WykL3OgcY92e2Vic4Ds[Y5q[yCEIHPlcIx{KHC{ZXnuZ5Vj[XSnZDDmc5IhOzBibXnud{Bnd2yub4fl[EBjgSCOUGOgc5IhTiijYjepNkBld26tZYmgZY51cS2vb4Xz[UBK\01iYX7kJJJm[2:vYnnuZY51KG2xdYPlJGlNPCC|dHnteYxifGmxbjDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliQXzhcYFzKEKudXWgdoVlfWO2aX;uJIF{e2G7LDDFR|UxKD1iMD6xJO69VS5? MoPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|A{QTVyMj:nQmNpTU2ETEyvZV4>
Sf21 NFPLbYFHfW6ldHnvckBie3OjeR?= NFzWflc2KG2rboO= NYn6fnI6UW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKHKnY3;tZolv[W62IH\1cIwudGWwZ4ToJIh2dWGwIICxNVBj\XSjL4XueIFo\2WmIILlZ49u[mmwYX70JIZ2dGxibHXu[5RpKHB6NXHsdIhiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jJzIHPlcIx{KHW|aX7nJJBpd3OyaHH0bYR6dGmwb4PpeI9tKGG|IIP1ZpN1emG2ZTDpckBxemW|ZX7j[UBw\iCpYX3tZU0{OlBvQWTQJIFnfGW{IEWgcYlveyCkeTD0bIlvKGyjLDDJR|UxKD1iMTFOwG0v M17UdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMxOzl3MEKvK|5EcEWPQly8M4E,
Sf21 M4DZUWZ2dmO2aX;uJIF{e2G7 MmTNOUBucW6| MnzLTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKHBzMUDhcJBp[S:3boTh[4dm\CC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBpfW2jbjDwPFVidHCqYTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBk\WyuczD1d4lv\yCyaH;zdIhifGmmeXzpco9{cXSxbDDhd{B{fWK|dILheIUhcW5icILld4Vv[2Vib3[g[4FudWFvM{LQMWFVWCCjZoTldkA2KG2rboOgZpkhNCCLQ{WwJF0hOTBizszNMi=> NEHh[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{ODN7NUCyM{c,S2iHTVLMQE9iRg>?
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p-MAPK / MAPK PI3Kγ / PI3Kδ 27174919 29522278
体内研究 IPI-145 按10 mg/kg剂量口服处理给药小鼠和大鼠,具有良好的药代动力学, Cmax 和AUC分别为390 ng/mL 和 137 ng•h/mL。IPI-145 (10 mg/kg) 有效作用于鼠DTH 模型,约~50% 耳肿胀。IPI-145 (10 mg/kg) 有效作用于大鼠胶原诱导的关节炎(CIA)模型,这种作用具有剂量依赖性。IPI-145 作用于大鼠CIA模型,防止发炎,且保护关节骨和软骨。IPI-145 (10 mg/kg,QD)有效作用于大鼠佐剂性多关节炎模型。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG400+0.5% Tween80+5% propylene glycol

30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 416.86
化学式

C22H17ClN6O

CAS号 1201438-56-3
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02307461 Completed Drug: IPI-145 (duvelisib)|Drug: IPI-145 Healthy SecuraBio November 2014 Phase 1
NCT02095587 Completed Drug: IPI-145 Hepatic Impairment SecuraBio March 2014 Phase 1
NCT01947777 Completed Drug: IPI-145|Drug: Rifampin Healthy SecuraBio October 2013 Phase 1
NCT01925911 Completed Drug: IPI-145|Drug: Midazolam Healthy SecuraBio August 2013 Phase 1
NCT01836861 Completed Drug: IPI-145 Healthy SecuraBio March 2013 Phase 1
NCT01549106 Completed Drug: IPI-145|Drug: Placebo Healthy Volunteers SecuraBio August 2011 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
Whether IPI-145 S7028 is mixture of two chiral forms, if not, which form is it?

回答:
S7028 IPI-145 is S form.